Clinical Trials Logo

Infection clinical trials

View clinical trials related to Infection.

Filter by:

NCT ID: NCT03162458 Completed - Clinical trials for Acute Upper Respiratory Infections

Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections

Start date: January 22, 2015
Phase: Phase 3
Study type: Interventional

Purpose of the study: - To assess efficacy of Anaferon for children liquid dosage form in the treatment of acute upper respiratory tract infections. - To assess safety of Anaferon for children liquid dosage form in the treatment of acute upper respiratory tract infections.

NCT ID: NCT03161951 Completed - Neuroinfections Clinical Trials

Differential Diagnostics of Etiology of Acute Infections

Start date: January 3, 2017
Phase:
Study type: Observational

Method for diagnostics of the origin of infections (bacterial vs viral) based on the identification of activation markers of blood neutrophils and monocytes will be developed.

NCT ID: NCT03160807 Recruiting - Clinical trials for Urinary Tract Infection

Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections

Levolet-KZ16
Start date: April 15, 2017
Phase: Phase 4
Study type: Interventional

Study is planned to evaluate safety and efficacy of Levolet in patients with complicated UTI

NCT ID: NCT03160105 Completed - HIV-1-infection Clinical Trials

Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV)

Simpl'HIV
Start date: May 19, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate whether maintenance antiretroviral therapy could be simplified to DTG + FTC dual therapy and/or patient-centered monitoring once virological suppression is achieved. Using a factorial design, the study aims to assess the efficacy of DTG + FTC dual therapy to maintain virological suppression through 48 weeks of follow-up as well as the costs of a patient-centered ART laboratory monitoring.

NCT ID: NCT03159403 Completed - Clinical trials for Gram-Positive Bacterial Infections

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

Start date: April 12, 2017
Phase: N/A
Study type: Observational

This study is a retrospective, observational study to evaluate oritavancin use in participants under real world conditions.

NCT ID: NCT03159364 Recruiting - Tuberculosis Clinical Trials

Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

Start date: July 15, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Epstein Barr Virus (EBV) or Cytomegalovirus (CMV) infection results in significant morbidity and mortality in hematopoietic stem cell transplantation (HSCT) patients. HSCT patients often face opportunistic infections due to the immunosuppressive state during transplantation. Antimicrobial drugs are usually used for prophylactic purposes and for treatment after early detectable infections. Unfortunately, some patients develop resistance to such drug treatment. In addition to HSCT patient, immune compromised patient may also be victim to opportunistic infections. Many infections can be effectively managed by functional immune recovery. In this study, the safety and efficacy of microbial-specific cytotoxic T lymphocytes (CTLs) will be investigated.

NCT ID: NCT03159078 Recruiting - Critical Illness Clinical Trials

Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens

MUSEUM
Start date: May 25, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of polymyxin B as monotherapy versus a combined polymyxin B-carbapenem therapy against multidrug-resistant (MDR) gram negative infections. The investigators intend to evaluate if this synergistic drug regimen correlates with improved outcomes against gram-negative infections in critically ill patients including: better clinical resolution, reduced length of stay at hospital, reduced length of stay at the intensive care unit, and less recurrence of infection.

NCT ID: NCT03158766 Completed - Infection Clinical Trials

Subclinical Propionibacterium Acnes Infection Estimation in the Intervertebral Disc (SPInE-ID)

SPInE-ID
Start date: May 31, 2017
Phase:
Study type: Observational

Subclinical infection of the intervertebral disc after lumbar disc herniation surgery has been correlated to chronic low back pain and vertebral endplate changes. The most commonly reported agent is Propionibacterium acnes. However, the real incidence is unclear, as it has been reported in some series ranging from 3.7% to 46%. Recently, a systematic review concluded that there is a relationship between P. acnes and endplate changes, but, there are so far no studies to verify whether the reported presence of that pathogen in the intervertebral discs is due to local infection or whether intraoperative contamination occurred during the collection of samples. Thus, the main objective of this study is to estimate the incidence of subclinical infection in patients surgically treated for lumbar disc herniation. To this end, a prospective cohort study will be conducted with a minimum of 95 patients between 18 and 65 years of age who have been submitted to surgery after failure of conservative treatment. The extruded disc will be removed and cultured for bacterial identification. As controls, the ligamentum flavum and the multifidus muscle, taken respectively before and after removal of the herniated fragment will also be cultured. Patients will be followed-up for a year and MRI will be done at the end of this period.

NCT ID: NCT03158077 Completed - HIV Infections Clinical Trials

Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection

KIRAL
Start date: November 15, 2016
Phase: N/A
Study type: Observational

Retrospective observational study, multicentric with Spanish hospitals, in which a switching or change strategy with RAL and ABC / 3TC guidelines was used, in the48 weeks before the start of the study, in order to determine parameters of Effectiveness and security.

NCT ID: NCT03154866 Not yet recruiting - Clinical trials for Microbial Colonization

Lactobacillus Kefiri LKF01 (DSM32079) in Newborns Born by Caesarian Section

Start date: June 1, 2017
Phase: Phase 4
Study type: Interventional

The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the first year of infants' life. Probiotics have been observed to positively influence the host's health, but to date few data about the ability of probiotics to modify the gut microbiota composition exist. 40 newborns born by elective caesarian sectional be randomized to a Lactobacillus kefiri LKF01 DSM32079 (LKEF) supplementation or placebo for 21 days. Changes in the gut microbiota composition were detected by using a Next Generation Sequencing technology.